[Paediatric malignant liver tumours]

Bull Cancer. 2012 Feb 1;99(2):219-28. doi: 10.1684/bdc.2011.1539.
[Article in French]

Abstract

Tumours and pseudotumours of the liver are a heterogeneous group of neoplasm including 60% of malignant tumours. Malignant liver tumours account for less than 2% of the lesions in children and vary considerably in incidence throughout the paediatric age range, with hepatoblastoma, rhabdoid tumour of the liver, hemangioendothelioma, biliary tract rhabdomysosarcoma and mesenchymal hamartoma in the first two years of life and hepatocellular carcinoma, focal nodular hyperplasia, and undifferentiated sarcoma in older children and adolescents. Treatment of malignant epithelial tumours is based on the surgical resection of the tumour associated with pre- and postoperative chemotherapy including cisplatinum. Modalities of the treatment are adapted to risk factors. Survival rates at three years are over 80% for localised hepatoblastoma whereas they are less than 30% in hepatocellular carcinomas. The role of targeted therapies still has to be defined.

Publication types

  • English Abstract
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adolescent
  • Age Factors
  • Biliary Tract Neoplasms / diagnosis
  • Biliary Tract Neoplasms / mortality
  • Biliary Tract Neoplasms / therapy
  • Carcinoma, Hepatocellular / diagnosis
  • Carcinoma, Hepatocellular / mortality
  • Carcinoma, Hepatocellular / therapy
  • Child
  • Child, Preschool
  • Hemangioendothelioma / diagnosis
  • Hemangioendothelioma / mortality
  • Hemangioendothelioma / therapy
  • Hepatoblastoma / diagnosis
  • Hepatoblastoma / mortality
  • Hepatoblastoma / therapy
  • Humans
  • Infant
  • Liver Neoplasms* / diagnosis
  • Liver Neoplasms* / mortality
  • Liver Neoplasms* / therapy
  • Rhabdoid Tumor / diagnosis
  • Rhabdoid Tumor / mortality
  • Rhabdoid Tumor / therapy
  • Rhabdomyosarcoma / diagnosis
  • Rhabdomyosarcoma / mortality
  • Rhabdomyosarcoma / therapy
  • Survival Rate